Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system.

Ipamorelin

Growth hormone secretagogue5 amino acids

BHuman Studies
85
Excellent Credibility
3 cited studies | Evidence level B

Ipamorelin is a selective growth hormone secretagogue that stimulates growth hormone release from the pituitary gland without significantly affecting cortisol or prolactin levels.

Mechanism of Action

Binds to ghrelin receptors (GHS-R1a) in the pituitary, triggering pulsatile GH release. Highly selective — does not stimulate ACTH, cortisol, or prolactin release.

Benefits

  • Selective GH release without cortisol elevation[2]
  • Improved body composition in clinical studies[1]
  • Enhanced bone mineral density[3]
  • Favorable side effect profile among GH secretagogues[1]
Not medical advice - research-reported information only

This content is for informational purposes only and does not constitute medical advice.

Ipamorelin - Dosing in Published Research

Reported routes: Subcutaneous injection, Intravenous
Clinical studies used 0.01-0.03 mg/kg IV or SC. Often paired with CJC-1295 in research protocols.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Transient headache[1]
  • Flushing[1]
  • Mild nausea[1]
  • Injection site reactions[1]
  • Water retention[1]

Considering peptide research?

Ipamorelin is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Get the Provider Checklist

Start with the evidence and provider checklist while routing is offline.

Always consult a professional

Research & Evidence

Compare Ipamorelin With

References

  1. 1.Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998. "Identified ipamorelin as the first GH secretagogue with selectivity comparable to GHRH itself" [PMID: 9849822]
  2. 2.Do growth hormone-releasing peptides act as ghrelin secretagogues?. Endocrine, 2001. "Confirmed dose-dependent GH release without affecting cortisol or prolactin in human subjects" [PMID: 11322495]
  3. 3.The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.. J Endocrinol, 2000. "Ipamorelin increased bone mineral content and periosteal bone formation in aged female rats" [PMID: 10828840]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Research Supplies

Equipment for responsible research-grade peptide handling and administration.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Ipamorelin FAQ